VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
ONCOOnconetix, Inc.
$0.98$613758
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
HomeStocksONCOBalance Sheet

Onconetix, Inc. (ONCO) Balance Sheet

7Y historyFree accessUpdated daily

The company's financial position is deteriorating rapidly, with total assets contracting from $87.5 million in 2023Q4 to $14.8 million in 2026Q1.

ONCO Balance Sheet

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19
Total Current Assets4.33M6.07M950.27K5.84M26.26M3.07M4.6M6.06M
Cash & Short-Term Investments3.72M5.22M646.5K4.55M25.75M1.93M4.31M6.05M
Cash Only3.72M5.22M646.5K4.55M25.75M1.93M4.31M6.05M
Short-Term Investments00000000
Accounts Receivable43.73K296.87K96.31K149.73K35.85K152.52K44.8K8.33K
Days Sales Outstanding55.18132.8913.93934.78----
Inventory137.64K149.96K64.08K364.05K0000
Days Inventory Outstanding360.82299.9915.92112.07----
Other Current Assets56.34K92K000757.65K00
Total Non-Current Assets10.5M18.86M27.23M81.68M52.71K11.5K215.6K21.93K
Property, Plant & Equipment74.26K85.86K182.32K209.2K14.09K11.5K15.67K6.93K
Fixed Asset Turnover10.82x9.50x13.84x0.28x----
Goodwill10.2M18.55M27.05M55.68M0000
Intangible Assets00025.41M0000
Long-Term Investments00250.31K00000
Other Non-Current Assets225K225K-250.31K383.54K38.62K0199.93K15K
Total Assets14.83M24.93M28.18M87.52M26.31M3.08M4.81M6.08M
Asset Turnover0.04x0.03x0.09x0.00x----
Asset Growth %-168.62%-11.55%-67.8%232.64%752.93%-35.9%-20.87%-
Total Current Liabilities3.07M9.14M18.29M17.19M3.92M1.64M68.67K75.76K
Accounts Payable1.53M1.76M3.79M5.3M1.5M582.61K68.67K18.38K
Days Payables Outstanding4.68K3.52K941.081.63K81.05K43.49K8.2K11.71K
Short-Term Debt247.2K09.33M9.62M0000
Deferred Revenue (Current)00000000
Other Current Liabilities1.02M7.05M230.04K490.22K1.15M234.26K00
Current Ratio1.41x0.66x0.05x0.34x6.69x1.88x66.94x79.98x
Quick Ratio1.37x0.65x0.05x0.32x6.69x1.88x66.94x79.98x
Cash Conversion Cycle-4.26K-3.08K-911.23-583.26----
Total Non-Current Liabilities18.31K24.36K280.88K68.92M009.64K6.86K
Long-Term Debt18.31K24.36K0118.86K0000
Capital Lease Obligations00074.29K0000
Deferred Tax Liabilities0003.07M0000
Other Non-Current Liabilities00280.88K65.66M009.64K6.86K
Total Liabilities3.08M9.16M18.57M86.11M3.92M1.64M78.31K82.62K
Total Debt289.92K48.77K9.45M9.89M0000
Net Debt-3.43M-5.17M8.8M5.33M-25.75M-1.93M-4.31M-6.05M
Debt / Equity0.02x0.00x0.98x7.04x----
Debt / EBITDA-0.04x-------
Net Debt / EBITDA0.51x-------
Interest Coverage-17.32x-17.68x-41.44x-54.72x----
Total Equity11.75M15.76M9.61M1.4M22.39M1.45M4.73M6M
Equity Growth %48.94%64.03%584.28%-93.73%1447.65%-69.44%-21.08%-
Book Value per Share18.694.8085.0179.751772.39127.21416.28527.49
Total Shareholders' Equity11.75M15.76M9.61M-5.6M22.39M1.45M4.73M6M
Common Stock2715118615732328
Retained Earnings-135.43M-131.21M-115.68M-56.79M-19.38M-5.96M-2.54M-939.87K
Treasury Stock-625.79K-625.79K-625.79K-625.79K-566.81K000
Accumulated OCI-441.2K-231.03K-2.72M2.38M000-8
Minority Interest0007.01M0000

Key Metrics

Growth RegimeContracting
ProfitabilityNegative
Balance SheetVulnerable
Cash FlowBurning
Top Statement Risk

Imminent liquidity and survival

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q1)

Balance Sheet Erosion Accelerates Rapidly

As reported in recent financial statements, Onconetix has seen its total assets decline from $87.5 million in 2023Q4 to $14.8 million in 2026Q1, a contraction that reflects the aggressive depletion of resources as the company struggles to establish a sustainable commercial footprint for its primary therapeutic assets.

The consistent reduction in total assets suggests that the company is consuming its capital base to fund ongoing operating losses rather than investing in productive capacity. This downward trajectory indicates that the current business model is failing to generate the necessary internal returns to stabilize the balance sheet.

Goodwill Impairment Risks Loom Large

Based on the provided quarterly data, goodwill has decreased from a peak of $55.7 million in 2023Q4 to $10.2 million in 2026Q1, which suggests that the company is actively writing down the value of past acquisitions as the commercial performance of its assets fails to meet expectations.

The significant reduction in intangible assets implies that the initial strategic rationale for acquiring its current product portfolio may have been overly optimistic. Investors should monitor whether further impairments are required, as the current carrying value of goodwill may still be disconnected from the reality of the company's declining revenue.

Liquidity Buffer Remains Critically Thin

According to the latest balance sheet, the current ratio has fluctuated significantly, reaching 1.41 in 2026Q1, yet this figure masks a precarious cash position of only $3.7 million that appears insufficient to support the company's high operating burn rate over the coming fiscal quarters.

While the current ratio shows a superficial improvement, the absolute cash balance remains dangerously low relative to the company's historical quarterly cash outflows. This suggests that the firm may be forced to seek dilutive financing or pursue emergency capital measures to maintain its status as a going concern.

Accumulated Deficit Undermines Equity Quality

As evidenced by the company's financial filings, the retained earnings balance has deteriorated to a deficit of $135.4 million as of 2026Q1, highlighting the persistent and substantial losses that have eroded shareholder equity and left the company with a fragile capital structure.

The deep and widening deficit in retained earnings indicates that the company has been unable to achieve profitability since its inception, relying instead on external capital to bridge the gap. This persistent erosion of equity suggests that the business model has yet to prove its fundamental viability in a competitive market.

ONCO — Frequently Asked Questions

Quick answers to the most common questions about buying ONCO stock.

What are the total assets of Onconetix, Inc. (ONCO)?

As of 2025, Onconetix, Inc. (ONCO) had total assets of $24.9M including $6.1M in current assets.

How much debt does Onconetix, Inc. (ONCO) have?

Onconetix, Inc. (ONCO) carries total debt of $0.0M, offset by $5.2M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.

What is the book value or shareholders' equity of Onconetix, Inc.?

Onconetix, Inc. (ONCO) has total shareholders' equity (book value) of $15.8M ($4.80 book value per share). Book value represents the net worth of the company belonging to common stock holders.

What is Onconetix, Inc.'s current ratio and liquidity?

Onconetix, Inc. (ONCO) reported a current ratio of 0.66x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.